U.S. market Closed. Opens in 12 hours 4 minutes

NAMS | NewAmsterdam Pharma Company N.V. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-31
Revenue14.09M97.50MN/AN/A
Cost of Revenue44.39K70.70K14.56KN/A
Gross Profit14.05M97.43M-14.56KN/A
Operating Expenses189.19M104.46M29.84M5.43M
Selling, General & Admin29.77M21.90M4.65M1.38M
Research & Development159.42M82.49M25.17M4.04M
Other Operating ExpensesN/A72.00K14.00K1.00K
Operating Income-182.97M-67.56M-29.83M-5.43M
Other Expenses / Income-5.23M-10.49M1.23M-320.00K
Before Tax Income-176.91M-78.05M-28.60M-5.75M
Income Tax Expenses27.00K70.83M216.00K344.00K
Net Income-176.94M-148.88M-28.82M-6.09M
Interest ExpensesN/A271.00K216.00K344.00K
Basic Shares Outstanding82.16M18.97M17.75M17.75M
Diluted Shares Outstanding82.16M18.97M17.75M17.75M
EBITDA-171.63M-6.88M-29.81M-5.43M
EBITDA Margin-1,218.13%-7.05%0.00%0.00%
EBIT-176.91M-77.78M-28.38M-5.41M
EBIT Margin-1,255.57%-79.78%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙